Literature DB >> 7459911

Percutaneous dilatation and recanalization of iliac and femoral arteries.

E Zeitler.   

Abstract

Five-year follow-up studies in patients with superficial femoral arterial occlusions and iliac artery stenoses have demonstrated a high success rate with percutaneous transluminal angioplasty performed by the Dotter technique. The special balloon catheters developed by Grüntzig, a standardized accessory pharmaceutical regimen, and more exact indications have further increased the rate of long-term success; the patency rates now approach 70% after three years. Clinical follow-up studies by Doppler ultrasound are useful for assessing the hemodynamic effects of the procedure.

Entities:  

Mesh:

Year:  1980        PMID: 7459911     DOI: 10.1007/bf02552727

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  2 in total

1.  TRANSLUMINAL TREATMENT OF ARTERIOSCLEROTIC OBSTRUCTION. DESCRIPTION OF A NEW TECHNIC AND A PRELIMINARY REPORT OF ITS APPLICATION.

Authors:  C T DOTTER; M P JUDKINS
Journal:  Circulation       Date:  1964-11       Impact factor: 29.690

2.  The treatment of occlusive arterial disease by transluminal catheter angioplasty.

Authors:  E Zeitler; W Schoop; W Zahnow
Journal:  Radiology       Date:  1971-04       Impact factor: 11.105

  2 in total
  3 in total

1.  Percutaneous transluminal recanalization of common iliac artery occlusions.

Authors:  Z J Rubinstein; B Morag; A Peer; A Bass; J Schneiderman
Journal:  Cardiovasc Intervent Radiol       Date:  1987       Impact factor: 2.740

Review 2.  Laser angioplasty of peripheral arteries: an epilogue?

Authors:  J Lammer
Journal:  Cardiovasc Intervent Radiol       Date:  1995 Jan-Feb       Impact factor: 2.740

3.  Total occlusion of iliac arteries: results of balloon angioplasty.

Authors:  A K Gupta; K Ravimandalam; V R Rao; S Joseph; M Unni; A S Rao; K S Neelkandhan
Journal:  Cardiovasc Intervent Radiol       Date:  1993 May-Jun       Impact factor: 2.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.